Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papo Matthias, Martinot Pauline, Sinico Renato A, Silvestre-Teixeira Vítor, Venhoff Nils, Urban Maria-Letizia, Iudici Michele, Mahrhold Juliane, Locatelli Francesco, Cassone Giulia, Schiavon Franco, Seeliger Benjamin, Neumann Thomas, Feder Claudia, Groh Matthieu, Marvisi Chiara, Samson Maxime, Barba Thomas, Jayne David, Troilo Arianna, Thiel Jens, Hellmich Bernhard, Monti Sara, Montecucco Carlomaurizio, Salvarani Carlo, Kahn Jean-Emmanuel, Bonnotte Bernard, Durel Cécile-Audrey, Puéchal Xavier, Mouthon Luc, Guillevin Loïc, Emmi Giacomo, Vaglio Augusto, Porcher Raphaël, Terrier Benjamin, French Vasculitis Study Group and the Eosinophilic Granulomatosis with Polyangiitis European Study Group
Аннотация
METHODS: This multicenter European retrospective cohort study included patients with EGPA fulfilling the 2022 American College of Rheumatology/EULAR criteria. Using Fine-Gray and logistic regression, we developed two multivariable prediction models, one for vasculitis relapse and another for GC-dependent asthma and/or ENT symptoms at 2 Internal validation was performed using bootstrapping.
RESULTS: A total of 809 patients were observed for a median of 72 months (interquartile range 37-115). Vasculitis relapse occurred in 228 patients with a 12-year cumulative incidence of 41.2% (95% confidence interval 36.3-46.8). GC-dependent asthma and/or ENT symptoms were observed in 66.4% at two years. Predictors of vasculitis relapse included age (nonlinear), GC-dependent asthma before EGPA diagnosis (hazard ratio [HR] 1.57), arthralgia (HR 1.27), myocarditis (HR 1.74), peripheral neuropathy (HR 1.39), myeloperoxidase-antineutrophil cytoplasmic antibody (HR 1.56), and baseline eosinophil count (nonlinear). Predictors of GC-dependent asthma and/or ENT symptoms included older age (odds ratio [OR] 0.98 per year), GC-dependent asthma at diagnosis (OR 1.50), chronic sinusitis (OR 1.78), and baseline eosinophil count (OR 0.70 per 109/L).
CONCLUSION: Using a large cohort with EGPA, we developed predictive models for vasculitis relapse and GC-dependent asthma and/or ENT symptoms. These tools may help guide treatment decisions. Prospective external validation in the current therapeutic era is warranted.